![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AstraZeneca’s Investigational Cancer Drug Fails in Eye Cancer Trial
AstraZeneca’s Investigational Cancer Drug Fails in Eye Cancer Trial
AstraZeneca’s investigational drug selumetinib has failed to meet its primary endpoint of progression free survival during a Phase 3 trial for a rare eye cancer.
Selumetinib, studied in combination with dacarbazine in patients with metastatic uveal melanoma, showed an adverse event profile, the company said this week.
The failure of the Phase 3 trial was surprising, after promising Phase 2 data on the indication, Berenberg analyst Alistair Campbell says in a note.
The findings of the trial won’t affect other studies of the drug, says Antoine Yver, head of oncology development at AZ. Selumetinib is being investigated primarily to treat advanced non-small cell lung cancer, but its usefulness in treating thyroid cancer and neurofibromatosis Type 1 also is being assessed. — Jonathon Shacat
Upcoming Events
-
21Oct